Ocular Therapeutix (OCUL) Long-Term Deferred Tax (2013)

Ocular Therapeutix's (OCUL) quarterly Long-Term Deferred Tax came in at $25.8 million in Q4 2013.

Ocular Therapeutix (OCUL) Long-Term Deferred Tax (2013) Analysis & Trends

Ocular Therapeutix's Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $25.8 million for Q4 2013.

On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $25.8 million in Q4 2013; TTM through Dec 2013 was $25.8 million, a N/A change from a year earlier, with the FY2013 full-year figure at $25.8 million, changed N/A from the prior year.
Long-Term Deferred Tax was little changed at $25.8 million in Q4 2013 per OCUL's latest filing.
Across five years, Long-Term Deferred Tax topped out at $25.8 million in Q4 2013 and bottomed at $25.8 million in Q4 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Ocular Therapeutix	1.91 Bn	1.91 Bn	9.46 Mn

Download Data

Date	Value
Dec 31, 2013	25.78 Mn